A Novel Estimation of the Relative Economic Value in Terms of Different Chronic Hepatitis B Treatment Options

Keyphrases

• Treatment Options 100%
• Entecavir 100%
• Chronic Hepatitis B 100%
• Hepatitis B Treatment 100%
• Relative Economics 100%
• Cost Savings 66%
• Days of Treatment 50%
• Lamivudine 50%
• Disease States 33%
• Economic Value 33%
• Treatment Value 33%
• Daily Cost 33%
• Decision Maker 16%
• Clinical Outcomes 16%
• Treatment Duration 16%
• Cirrhosis 16%
• Hepatocellular Carcinoma 16%
• Published Data 16%
• Fibrosis 16%
• Disease Progression 16%
• Health Status 16%
• Estimated Cost 16%
• Therapeutic Value 16%
• Clinical Benefit 16%
• Liver Transplantation 16%
• State Transition Model 16%
• Treatment Initiation 16%
• Payers 16%
• Patient Treatment 16%
• Model Output 16%
• Chronic Hepatitis B Patients 16%
• Naïve Patients 16%
• Chronic Hepatitis B Infection 16%
• Advanced Fibrosis 16%
• Telbivudine 16%
• Decompensated Cirrhosis 16%
• Mild Disease 16%
• Natural History Data 16%
• Healthcare Decisions 16%
• Prescribers 16%
• Complicated Disease 16%
• Suboptimal Responders 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Chronic Hepatitis B 100%
• Entecavir 100%
• Disease 50%
• Lamivudine 50%
• Fibrosis 33%
• Infection 16%
• Liver Cell Carcinoma 16%
• Liver Cirrhosis 16%
• Disease Exacerbation 16%
• Health Status 16%
• Telbivudine 16%
• Decompensated Liver Cirrhosis 16%